Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Sponsor: Novartis Pharmaceuticals
Summary
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.
Official title: A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
275
Start Date
2019-09-18
Completion Date
2030-02-27
Last Updated
2026-06-22
Healthy Volunteers
No
Conditions
Interventions
Tulmimetostat
Tulmimetostat dosed once per day orally in 28 day cycles
Enzalutamide
Enzalutamide dosed once per day orally in 28 day cycles
Locations (81)
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Emory University School of Medicine
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Loyola University Medical Center
Maywood, Illinois, United States
University of Maryland Medical Ctr
Baltimore, Maryland, United States
Massachusetts General Hospital (MGH)
Boston, Massachusetts, United States
Dana Farber Cancer Institute (HARVARD)
Boston, Massachusetts, United States
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
NYU Langone Medical Center
New York, New York, United States
Weill Medical College of Cornell University
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of Rochester Medical Center
Rochester, New York, United States
Montefiore Einstein Center for Cancer Care (MECCC)
The Bronx, New York, United States
University of Cincinnati Cancer Institute
Cincinnati, Ohio, United States
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
South Texas Accelerated Research Therapeutics (START) - San Antonio
San Antonio, Texas, United States
South Texas Accelerated Research Therapeutics (START) - Midwest Location
San Antonio, Texas, United States
University of Virginia Health System (UVAHS)
Charlottesville, Virginia, United States
Swedish Cancer Institute
Seattle, Washington, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
CHU Bordeaux Hopital Saint Andre
Bordeaux, France
CLCC Institut Bergonie
Bordeaux, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
CHU Nantes Hopital Hotel Dieu
Nantes, France
CHU Nantes Hopital Hotel Dieu
Nantes, France
CHU Nantes Hopital Nord Laennec
Saint-Herblain, France
Institut Cancerologie de Strasbourg
Strasbourg, France
CLCC Institut Gustave Roussy
Villejuif, France
Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi
Bologna, Italy
Fondazione IRCCS Istituto Nazionale Dei Tumori
Milan, Italy
National Cancer Institute, IRCCS
Milan, Italy
European Institute of Oncology (IEO), IRCCS ( Department of Urogenital and Head-and-Neck Medical Oncology)
Milan, Italy
European Institute of Oncology (IEO), IRCCS
Milan, Italy
Humanitas San Pio X
Milan, Italy
IRCCS Policlinico Universitario Fondazione Agostino Gemelli
Roma, Italy
IRCCS Istituto Clinico Humanitas - Research Hospital
Rozzano, Italy
Uniwersyteckie Centrum Kliniczne GUMed
Gdansk, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
Gliwice, Poland
Pratia MCM
Krakow, Poland
Institute of Polish Mother Health Centre - ICZMP
Lodz, Poland
Centrum Medyczne Pratia - Poznan
Poznan, Poland
University Teaching Hospital
Poznan, Poland
Novartis Investigative Site
Daegu, South Korea
National Cancer Center
Goyang-si Gyeonggi-do, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
Seoul National University Hospital
Seoul, South Korea
Yonsei Univ Health System YUCM
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Gangnam Severance Hospital
Seoul, South Korea
The Catholic University of Korea, Yeouido St. Mary's Hospital
Seoul, South Korea
Hospital Vall d Hebron
Barcelona, Spain
Hospital Clinic of Barcelona
Barcelona, Spain
Catalan Institute of Oncology
Barcelona, Spain
Hospital Universitari de Girona Doctor Josep Trueta
Girona, Spain
University Hospital Ramon y Cajal
Madrid, Spain
University Hospital Clinical San Carlos, Department of Medical Oncology
Madrid, Spain
University Hospital Foundation Jimenez Diaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Puerta de Hierro Majadahonda University Hospital
Majadahonda, Spain
Hospital Universitario Son Espases
Palma, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Hospital Universitario Quirónsalud Madrid
Pozuelo de Alarcón, Spain
Parc Taulí Hospital Universitari
Sabadell, Spain
Hematology Department - Hospital Universitario de Salamanca, IBSAL, CIBERONC
Salamanca, Spain
Santiago Clinic Hospital CHUS
Santiago de Compostela, Spain
Hospital Virgen del Rocio
Seville, Spain
Instituto Valenciano de Oncologia
Valencia, Spain
La Fe University and Polytechnic Hospital
Valencia, Spain
Royal United Hospital Bath NHS Trust
Bath, United Kingdom
Leicester General Hospital
Leicester, United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Churchill Hospital
Oxford, United Kingdom
Southampton General Hospital
Southampton, United Kingdom
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH)
Sutton, United Kingdom
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH)
Sutton, United Kingdom
Musgrove Park Hospital
Taunton, United Kingdom